Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Current Assets readings, the most recent being $1.0 billion for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 28.63% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, up 28.63%, and an annual FY2025 reading of $1.0 billion, up 28.63% over the prior year.
  • Current Assets hit $1.0 billion in Q4 2025 for Apellis Pharmaceuticals, up from $990.7 million in the prior quarter.
  • The five-year high for Current Assets was $1.1 billion in Q1 2022, with the low at $475.4 million in Q3 2021.
  • Median Current Assets over the past 5 years was $817.7 million (2021), compared with a mean of $826.8 million.
  • The sharpest move saw Current Assets plummeted 35.96% in 2021, then soared 74.99% in 2022.
  • Year by year, Current Assets stood at $824.0 million in 2021, then decreased by 12.68% to $719.5 million in 2022, then rose by 6.51% to $766.3 million in 2023, then rose by 2.95% to $789.0 million in 2024, then rose by 28.63% to $1.0 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $1.0 billion, $990.7 million, and $755.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.